FDA approved Imlygic (talimogene laherparepvec) as the first oncolytic viral therapy in the U.S.
Lillian L. Siu discovered her passion while perusing employment ads in the Journal of Clinical Oncology.
FDA Approves Imlygic as First Oncolytic Viral Therapy in the U.S., for Melanoma
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.
If the FDA Oncology Center of Excellence (OCE) began an “innovation challenge” in oncology drug development, what would that look like?
“How often do you receive financial support from parents or other relatives?”
Todd Golub, director and founding core member of the Broad Institute of MIT and Harvard, appeared on the Cancer Luminaries podcast, a series launched by the UChicago Medicine Comprehensive Cancer Center to mark its 50th year as a National Cancer Institute-designated center.
Norman Wolmark, chairman of the NSABP Foundation Inc., and group chair and contact principal investigator of NRG Oncology, received the 2024 American Surgical Association Medallion for Advancement of Surgical Care at the American Surgical Association’s 144th annual meeting in Washington, DC.
